- Home
- SEI vs CCCC Comparison
SEI vs CCCC Comparison
Compare SEI & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEI
- CCCC
- Stock Information
- Founded
- SEI 2014
- CCCC 2015
- Country
- SEI United States
- CCCC United States
- Employees
- SEI N/A
- CCCC N/A
- Industry
- SEI
- CCCC Biotechnology: Pharmaceutical Preparations
- Sector
- SEI
- CCCC Health Care
- Exchange
- SEI NYSE
- CCCC Nasdaq
- Market Cap
- SEI 400.7M
- CCCC 405.6M
- IPO Year
- SEI 2017
- CCCC 2020
- Fundamental
- Price
- SEI $13.32
- CCCC $6.16
- Analyst Decision
- SEI
- CCCC Buy
- Analyst Count
- SEI 0
- CCCC 6
- Target Price
- SEI N/A
- CCCC $10.50
- AVG Volume (30 Days)
- SEI 242.9K
- CCCC 712.7K
- Earning Date
- SEI 11-04-2024
- CCCC 10-30-2024
- Dividend Yield
- SEI 3.59%
- CCCC N/A
- EPS Growth
- SEI N/A
- CCCC N/A
- EPS
- SEI 0.65
- CCCC N/A
- Revenue
- SEI $274,799,000.00
- CCCC $29,378,000.00
- Revenue This Year
- SEI N/A
- CCCC $39.70
- Revenue Next Year
- SEI $7.99
- CCCC N/A
- P/E Ratio
- SEI $20.66
- CCCC N/A
- Revenue Growth
- SEI N/A
- CCCC 83.26
- 52 Week Low
- SEI $6.59
- CCCC $1.06
- 52 Week High
- SEI $14.40
- CCCC $11.88
- Technical
- Relative Strength Index (RSI)
- SEI N/A
- CCCC 54.49
- Support Level
- SEI N/A
- CCCC $6.02
- Resistance Level
- SEI N/A
- CCCC $7.14
- Average True Range (ATR)
- SEI 0.00
- CCCC 0.37
- MACD
- SEI 0.00
- CCCC 0.09
- Stochastic Oscillator
- SEI 0.00
- CCCC 58.96
About SEI SOLARIS ENERGY INFRASTRUCTURE INC
Solaris Energy Infrastructure Inc provides services in the oil and gas industry. Its solutions are Solaris software suite, Fluid management system, Automated control systems, Field services, Last mile management, Wet sand solutions, Power Solutions, and Integrated wellsite solution.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a biopharmaceutical company advancing targeted protein degradation science to develop a new generation of small-molecular medicines to transform how the disease is treated. Its TORPEDO platform enables the discovery of a new class of targeted investigational small-molecule medicines called protein degraders.